Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by TheRock07on May 16, 2016 8:33am
122 Views
Post# 24876070

RE:PFE is buying ANAC

RE:PFE is buying ANACBecause it is cheaper to buy drugs than to develop, test and get approval.

ANAC ( market cap of $3 billion )  has annual sales of about $100 million and losing tons of money.
It has some promising advanced drugs too.

But, very expensive at 30 times annual sales.

Major  up gaps are developing across all of the pharma/biotech indices this am, as a result of the developing momentum in M & A in this sector
.
As i posted earlier, the bull market is resuming in pharmas and biotechs, after being beaten down by illegal short and distort attacks for the past 8-9 months.

Onwards and upwards to former highs
<< Previous
Bullboard Posts
Next >>